In a preclinical study by Xie et al. conducted on osteosarcoma cell lines, treatment with lurbinectedin was associated with the stimulation of ICD as demonstrated by multiple cell modifications, such as the translocation of calreticuline (CALR) at the cell surface, the generation of an autocrine and paracrine response mediated by type I interferons, and the release of nuclear high mobility group box 1 (HMGB1), which is involved in tumor antigen recognition. The gene discussed is CALR; the disease is osteosarcoma.